

Disclosure of acquisition of treasury shares

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 12 January 2015 - Fagron discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Fagron today announces that during the period from 5 January 2015 to 9 January 2015, it acquired 20,000 treasury shares on Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
5 January 2015	-	-	-	-	-
6 January 2015	-	-	-	-	-
7 January 2015	12,500	€ 33.0792	€ 32.90	€ 33.37	€ 413,490
8 January 2015	7,500	€ 32.7904	€ 32.63	€ 33.00	€ 245,928
9 January 2015	-	-	-	-	-

Prior to the transactions, Fagron held 577,479 treasury shares. As a result of the acquisition of 20,000 treasury shares, Fagron now holds 597,479 treasury shares, representing 1.90% of the total number of shares outstanding.

Fagron will publish a weekly update every Monday provided that shares were bought back in the preceding week.

¹This press release was sent out by Fagron NV and Fagron BV.



Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com

investors.fagron.com

